Saudi Chemical Holding Company

SASE:2230 Rapport sur les actions

Capitalisation boursière : ر.س8.4b

Saudi Chemical Holding Résultats passés

Passé contrôle des critères 5/6

Saudi Chemical Holding a connu une croissance annuelle moyenne de ses bénéfices de 39.4%, tandis que le secteur Healthcare a vu ses bénéfices augmenter de en hausse à 20.3% par an. Les revenus ont augmenté de en hausse à un taux moyen de 13.8% par an. Le rendement des capitaux propres de Saudi Chemical Holding est 16% et ses marges nettes sont de 5.4%.

Informations clés

39.4%

Taux de croissance des bénéfices

39.4%

Taux de croissance du BPA

Healthcare Croissance de l'industrie12.3%
Taux de croissance des recettes13.8%
Rendement des fonds propres16.0%
Marge nette5.4%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Recent updates

Here's Why Saudi Chemical Holding (TADAWUL:2230) Has Caught The Eye Of Investors

Oct 24
Here's Why Saudi Chemical Holding (TADAWUL:2230) Has Caught The Eye Of Investors

There's Been No Shortage Of Growth Recently For Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital

Sep 09
There's Been No Shortage Of Growth Recently For Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital

Saudi Chemical Holding Company's (TADAWUL:2230) P/E Is On The Mark

May 28
Saudi Chemical Holding Company's (TADAWUL:2230) P/E Is On The Mark

Investors Met With Slowing Returns on Capital At Saudi Chemical Holding (TADAWUL:2230)

May 07
Investors Met With Slowing Returns on Capital At Saudi Chemical Holding (TADAWUL:2230)

With EPS Growth And More, Saudi Chemical Holding (TADAWUL:2230) Makes An Interesting Case

Mar 06
With EPS Growth And More, Saudi Chemical Holding (TADAWUL:2230) Makes An Interesting Case

Saudi Chemical Holding Company's (TADAWUL:2230) 26% Jump Shows Its Popularity With Investors

Feb 10
Saudi Chemical Holding Company's (TADAWUL:2230) 26% Jump Shows Its Popularity With Investors

Saudi Chemical Holding (TADAWUL:2230) Is Reinvesting At Lower Rates Of Return

Oct 31
Saudi Chemical Holding (TADAWUL:2230) Is Reinvesting At Lower Rates Of Return

Here's Why We Think Saudi Chemical Holding (TADAWUL:2230) Might Deserve Your Attention Today

Jul 06
Here's Why We Think Saudi Chemical Holding (TADAWUL:2230) Might Deserve Your Attention Today

Saudi Chemical Holding (TADAWUL:2230) Is Due To Pay A Dividend Of SAR0.50

Jan 09
Saudi Chemical Holding (TADAWUL:2230) Is Due To Pay A Dividend Of SAR0.50

Saudi Chemical Holding (TADAWUL:2230) Has Affirmed Its Dividend Of SAR0.50

Dec 22
Saudi Chemical Holding (TADAWUL:2230) Has Affirmed Its Dividend Of SAR0.50

Here's What's Concerning About Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital

Sep 14
Here's What's Concerning About Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital

Saudi Chemical Holding (TADAWUL:2230) Will Be Hoping To Turn Its Returns On Capital Around

Dec 06
Saudi Chemical Holding (TADAWUL:2230) Will Be Hoping To Turn Its Returns On Capital Around

Does It Make Sense To Buy Saudi Chemical Holding Company (TADAWUL:2230) For Its Yield?

Apr 19
Does It Make Sense To Buy Saudi Chemical Holding Company (TADAWUL:2230) For Its Yield?

Here's What's Concerning About Saudi Chemical's (TADAWUL:2230) Returns On Capital

Mar 29
Here's What's Concerning About Saudi Chemical's (TADAWUL:2230) Returns On Capital

Is Saudi Chemical Company's (TADAWUL:2230) 2.8% ROE Worse Than Average?

Mar 01
Is Saudi Chemical Company's (TADAWUL:2230) 2.8% ROE Worse Than Average?

Does Saudi Chemical's (TADAWUL:2230) Share Price Gain of 41% Match Its Business Performance?

Feb 01
Does Saudi Chemical's (TADAWUL:2230) Share Price Gain of 41% Match Its Business Performance?

How Has Saudi Chemical (TADAWUL:2230) Allocated Its Capital?

Dec 28
How Has Saudi Chemical (TADAWUL:2230) Allocated Its Capital?

Should You Be Concerned About Saudi Chemical Company's (TADAWUL:2230) ROE?

Nov 30
Should You Be Concerned About Saudi Chemical Company's (TADAWUL:2230) ROE?

Ventilation des recettes et des dépenses

Comment Saudi Chemical Holding gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

SASE:2230 Recettes, dépenses et bénéfices (SAR Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 246,0223263640
30 Jun 245,8692883700
31 Mar 245,4602423680
31 Dec 234,8551833560
30 Sep 234,5211173530
30 Jun 234,081933360
31 Mar 233,831803220
31 Dec 223,696803100
30 Sep 223,378512950
30 Jun 223,402482850
31 Mar 223,346612920
31 Dec 213,411702900
30 Sep 213,491532640
30 Jun 213,517642700
31 Mar 213,476772590
31 Dec 203,306742670
30 Sep 203,066463280
30 Jun 202,991413400
31 Mar 202,909323420
31 Dec 192,949333340
30 Sep 193,2261013010
30 Jun 193,1201012800
31 Mar 192,998982630
31 Dec 182,9491152450
30 Sep 182,7681282200
30 Jun 182,6501432110
31 Mar 182,5411432090
31 Dec 172,4741422110
30 Sep 172,2741291960
30 Jun 172,2061191960
31 Mar 172,2791381970
31 Dec 162,1431341940
30 Sep 162,2581682120
30 Jun 162,3031852100
31 Mar 162,3202162100
31 Dec 152,4102512070
30 Sep 152,4132661900
30 Jun 152,4522701960
31 Mar 152,4702791870
31 Dec 142,4842841860
30 Sep 142,5662921890
30 Jun 142,4503131720
31 Mar 142,3593031690
31 Dec 132,2753011630

Des revenus de qualité: 2230 a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de 2230 sont plus élevées que l'année dernière 2230. (5.4%) sont plus élevées que l'année dernière (2.6%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de 2230 ont augmenté de manière significative de 39.4% par an au cours des 5 dernières années.

Accélération de la croissance: La croissance des bénéfices de 2230 au cours de l'année écoulée ( 178.1% ) dépasse sa moyenne sur 5 ans ( 39.4% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices 2230 au cours de l'année écoulée ( 178.1% ) a dépassé celle du secteur Healthcare 15.7%.


Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de 2230 ( 16% ) est considéré comme faible.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé